A Phase II Study of PM01183 as Second-line Treatment in Patients with Metastatic Pancreatic Cancer
Read time: 1 mins
Last updated:10th Mar 2011
To evaluate the antitumor activity of PM01183 in terms of overall survival rate at 6 months (OS6) in patients with metastatic pancreatic cancer.
|Study start date||2011-03-10|